Table 4.
Change in plasma biomarkers (significance changes highlighted in grey).
| Plasma biomarker | Baseline | Week 1 | Week 2 |
|---|---|---|---|
| Median [interquartile ranges]; n (patients) | |||
| VEGF (pg/ml) | 68.8 [56.8, 104.2] n=17 |
109.8 [73.4, 178.2] n=19 |
211.2 [155.4, 323.4] n=17 |
| P value* | N/A | 0.0026 | 0.0004 |
|
| |||
| PlGF (pg/ml) | 43.4 [38.5, 50.8] n=17 |
58.3 [45.6, 80.7] n=19 |
97.4 [79.8, 130.2] n=17 |
| P value | N/A | <0.0001 | <0.0001 |
|
| |||
| SDF1α (pg/ml) | 2089 [1882, 2395] n=17 |
2265 [1991, 2602] n=19 |
2337 [2203, 2464] n=17 |
| P value | N/A | 0.0001 | 0.0006 |
|
| |||
| VEGF-D (pg/ml) | 1098.4 [907.5, 1823.2] n=17 |
1414.7 [1203.8, 2404.1] n=19 |
1820.8 [1459.9, 2720.2] n=17 |
| P value | N/A | <0.0001 | <0.0001 |
|
| |||
| TIMP-1 (ng/ml) | 229.0 [171.6, 338.5] n=17 |
160.9 [126.5, 214.4] n=19 |
149.6 [131.7, 190.9] n=17 |
| P value | N/A | <0.0001 | <0.0001 |
|
| |||
| Ang-2 (pg/ml) | 3423.3 [2838.6, 4534.1] n=17 |
3277.4 [2356.9, 4326.9] n=19 |
2792.1 [2200.2, 3458.8] n=17 |
| P value | N/A | 0.0067 | 0.0015 |
|
| |||
| TNF-α (pg/ml) | 2.82 [2.10, 3.67] n=17 |
2.59 [1.83, 3.13] n=19 |
2.45 [1.69, 3.14] n=17 |
| P value | N/A | 0.0046 | 0.0002 |
|
| |||
| IFN-γ (pg/ml) | 9.2 [6.5, 19.9] n=17 |
7.6 [6.1, 13.2] n=19 |
14.9 [8.8, 19.7] n=17 |
| P value | N/A | 0.013 | 0.33 |
|
| |||
| IL-10 (pg/ml) | 0.47 [0.38, 0.77] n=17 |
0.42 [0.35, 0.65] n=19 |
0.45 [0.35, 0.58] n=17 |
| P value | N/A | 0.022 | 0.094 |
|
| |||
| Free IGF-I (ng/ml) | 0.664 [0.517, 0.811] n=17 |
0.633 [0.511, 0.967] n=19 |
0.991 [0.677,1.329] n=17 |
| P value | N/A | 0.2247 | 0.0004 |
|
| |||
| sTie-2 (pg/ml) | 5950.7 [5398.5, 6580.7] n=17 |
6333.3 [5567.8, 6834.6] n=19 |
6225.3 [5468.2, 7995.5] n=17 |
| P value | N/A | 0.051 | 0.026 |
|
| |||
| sVEGFR-2 (pg/ml) | 7903 [6091, 8683] n=17 |
7961 [5974, 8905] n=19 |
6375 [5182, 6751] n=17 |
| P value | N/A | 0.38 | 0.0026 |
|
| |||
| HGF (pg/ml) | 1490.0 [1242.5, 1959.8] n=17 |
1289.7 [1030.1, 2328.5] n=19 |
1254.3 [1065.5, 1582.6] n=17 |
| P value* | N/A | 0.16 | 0.030 |
|
| |||
| IL-8 (pg/ml) | 42.6 [20.6, 145.0] n=17 |
29.8 [15.5, 71.5] n=19 |
21.0 [11.8, 43.2] n=17 |
| P value | N/A | 0.051 | 0.0004 |
|
| |||
| sMET (ng/ml) | 1348.4 [1287.5, 1597.6] n=16 |
1479.3 [1305.1, 1772.7] n=19 |
1519.4 [1323.5, 1901.2] n=17 |
| P value | N/A | 0.16 | 0.11 |
|
| |||
| CAIX (pg/ml) | 208.2 [92.6, 251.3] n=9 |
205.6 [129.4, 255.8] n=10 |
205.6 [129.4, 255.8] n=10 |
| P value | N/A | 0.30 | 0.65 |
|
| |||
| Ang-1 (pg/ml) | 1030.7 [62.5, 1328.6] n=17 |
62.5 [62.5, 1277.8] n=19 |
62.5 [62.5, 1341.4] n=17 |
| P value | N/A | 0.92 | 0.34 |
|
| |||
| bFGF (pg/ml) | 13.3 [5.5, 17.3] n=17 |
13.8 [8.5, 17.3] n=19 |
14.5 [8.1, 22.7] n=17 |
| P value | N/A | 0.96 | 0.52 |
|
| |||
| sVEGFR-1 (pg/ml) | 105.9 [71.4, 206.3] n=17 |
74.9 [55.7, 257.6] n=19 |
74.2 [58.3, 173.8] n=17 |
| P value | N/A | 0.12 | 0.72 |
|
| |||
| VEGF-C (pg/ml) | 83.0 [83.0, 83.0] n=17 |
83.0 [83.0, 105.9] n=19 |
83.0 [83.0, 94.7] n=17 |
| P value | N/A | 0.22 | 0.50 |
|
| |||
| IL-12 p70 (pg/ml) | 0.48 [0.48, 0.56] n=17 |
0.48 [0.48-0.48] n=19 |
0.48 [0.48, 0.56] n=17 |
| P value | N/A | 0.81 | 0.22 |
|
| |||
| IL-2 (pg/ml) | 0.69 [0.69, 0.71] n=17 |
0.69 [0.69, 0.76] n=19 |
0.69 [0.69, 0.80] n=17 |
| P value | N/A | 0.30 | 0.95 |
|
| |||
| IL-6 (pg/ml) | 3.16 [2.01, 5.83] n=17 |
2.81 [1.24, 3.66] n=19 |
3.04 [2.13, 4.70] n=17 |
| P value | N/A | 0.089 | 0.52 |
Median and IQR for IL-1β and IL-4 were not tabulated because the majority of them had median values under the detectable threshold.
P values were from Wilcoxon signed rank test.
Abbreviations: Ang, angiopoietin; bFGF, basic fibroblast growth factor; CAIX, carbonic anhydrase IX; HGF, hepatocyte growth factor; IFN-γ, interferon gamma; IGF, insulin-like growth factor; IL, interleukin; IQR, interquartile range; PlGF, placental growth factor; SDF1α, stromal cell-derived factor 1 alpha; sVEGFR, soluble vascular endothelial growth factor receptor; sMET, soluble MET; TIMP, tissue inhibitor of matrix metalloproteinase; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.